COYA-302

N/A

Report date: 2026/05/13 17:57:39

Base Information

Drug NameCOYA-302
Drug Alias NameCOYA-302COYA302COYA 302
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionCytotoxic T-Lymphocyte-Associated Antigen 4 agonistsInterleukin-2 agonists
TargetsInterleukin-2Cytotoxic T-Lymphocyte-Associated Antigen 4
Therapy Area/IndicationsAmyotrophic Lateral SclerosisFrontotemporal DementiaParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCoya Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesCoya Therapeutics IncDr.Reddy's Laboratories Ltd
Inactive CompaniesN/A
Active IndicationsAmyotrophic Lateral SclerosisFrontotemporal DementiaParkinson Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A